explore
 
  • Tasigna Daily Planner

    The Tasigna Daily Planner is a web-app that works from any device, from your smartphone to your laptop or tablet. Use it to plan your Tasigna dosing schedule.

    Start Now (no download necessary)
 
  • Patients with BCR-ABL ≤ 10% at 3 months with Tasigna vs Imatinib

    Early Molecular Response (EMR) in CML

    ENESTnd participants without evaluable PCR samples at 3 months were excluded from the Landmark Analysis.3 TASIGNA 400 mg BID ENESTnd study arm is not reported here as this dose is not indicated for newly diagnosed patients.1

  • Patients Alive by 6 years1

    Early Molecular Response (EMR) in CML

    *Pooled analysis of patients on TASIGNA 300 mg BID and imatinib.

References
  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; September 2016.
  2. Baccarani M, et al. Blood. 2013; 122(6):872-884.
  3. Hughes T, et al. Blood. 2014: 123(9):1353-1359.
 
  • Cumulative Rate of MMR by 6 Years in ENESTnd1

    ENESTnd MMR Rates 6 Years
  • Percent of Patients With MMR by 1 Year in ENESTnd1

    Major Molecular Response 1 Year Tasigna
  • Cumulative Rate of MR4.5 by 6 Years in ENESTnd1

    CML MR 4.5 Randomization
  • Percent of Patients With MR4.5 by 6 Years in ENESTnd1

    MR 4.5 Nilotinib vs Imatinib
References
  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; September 2016.
 
  • 99% of patients treated with TASIGNA 300 mg BID1

    Remained In Chronic Phase at 6 Years (n = 282)1

    Chronic Phase CML and Tasigna Chronic Phase CML and Tasigna Chronic Phase CML and Tasigna

    *In patients still receiving study treatment.

  • Patients Who Progressed1

    CML Progression on Tasigna
References
  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; September 2016.
  2. Larson RA, et al. JCO. 2013;31(18s) [abstract 7052].
  3. Larson RA, et al. JCO. 2014;32(5s) [abstract 7073].